Study of ORIC-101 in Combination With Anticancer Therapy
Public ClinicalTrials.gov record NCT03928314. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT03928314
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- ORIC-101 Drug
- Nab-paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1, 2019
- Primary completion
- Sep 21, 2022
- Completion
- Dec 3, 2023
- Last update posted
- Dec 14, 2023
2019 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Institute | Palo Alto | California | 94304 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| University of Colorado - PPDS | Aurora | Colorado | 80045 | — |
| Florida Cancer Specialists & Research Institute | Lake Mary | Florida | 32746 | — |
| Florida Cancer Specialists & Research Institute | Sarasota | Florida | 34232 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Tennessee Oncology NASH - SCRI - PPDS | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research Centers - Medical City | Dallas | Texas | 75231 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| University of Utah - Huntsman Cancer Institute - PPDS | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03928314, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03928314 live on ClinicalTrials.gov.